Scibase: Year-end report

Scibase: Year-end report

PR Newswire

STOCKHOLM, Feb. 19, 2021

STOCKHOLM, Feb. 19, 2021 /PRNewswire/ -- January 1 - December 31, 2020

The fourth quarter in figures:

The full year in figures:

Important events during the quarter:

Important events after the end of the  period

 


July 1 - Sep 30

Jan 1 - Sep 30

THE GROUP

2020

2019

2020

2019

Net sales, SEK ths

3 055

2 800

9 521

9 276

Gross margin, %

49,4%

58,0%

52,5%

54,5%

Equity/Asset ratio, %

79,1%

69,4%

79,1%

69,4%

Net indebtness, multiple

0,26

0,44

0,26

0,44

Cash equivalents, SEK ths

41 427

26 456

41 427

26 456

Cashflow from operating activities, SEK ths

-10 290

-8 842

-33 861

-37 956

Earnings per share (before and after dilution), SEK

-0,20

-0,61

-1,12

-2,38

Shareholder's equity per share, SEK

0,96

1,93

1,50

1,93

Average number of shares, 000'

48 707

16 618

31 287

16 618

Number of shares at closing of period, 000'

54 780

16 618

54 780

16 618

Share price at end of period, SEK

4,62

4,36

4,62

4,36

Number of sold electrodes, pieces

7 492

7 180

25 686

23 724

Average number of employees

17

18

16

18

 

This information is information that SciBase Holding AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out below, at 08.00 CET on February 19, 2021.Contact person: Michael Colérus, CFO. +46 70 341 34 72

For more information, please contact: 

Simon Grant, CEO SciBase 
Phone: +46 72 887 43 99 
Email: simon.grant@scibase.com

Certified Advisor: 

Avanza AB 
Phone: +46 8 409 421 20 
Email: ca@avanza.se

About SciBase and Nevisense

SciBase AB is a global medical technology company based in Stockholm, Sweden that develops unique point-of-care devices for the evaluation of skin disorders such as skin cancer and atopic dermatitis. SciBase's first product, Nevisense, helps clinicians detect melanoma, the most dangerous type of skin cancer. Further development has led to Nevisense also being used as a tool to assess the skin barrier and non-melanoma skin cancer. Nevisense is based on substantial research and has achieved excellent results in the largest clinical study ever conducted on the detection of malignant melanoma. Nevisense is CE marked in Europe, has TGA approval in Australia and an FDA approval (PMA) in the United States. SciBase technology is based Electrical Impedance Spectroscopy (EIS) combined with Artificial Intelligence (AI) algorithms that interpret the varying electrical properties of human tissue to detect malignancies and abnormalities. SciBase Holding AB is listed on First North Growth Market ("SCIB"). Further information is available at www.scibase.com.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/scibase/r/year-end-report,c3290034

The following files are available for download:

https://mb.cision.com/Main/12371/3290034/1375383.pdf

Release

Voltar noticias em Inglês